What is Vizgen?
Vizgen is a pioneering force in the field of spatial genomics, dedicated to mapping the complex biological systems that govern human health and disease. At the core of its technological suite is the MERSCOPE platform, which facilitates massively multiplexed, genome-scale nucleic acid imaging at subcellular resolution. This capability allows researchers to visualize biological processes with unprecedented spatial context, providing essential data for breakthroughs in oncology, immunology, and neuroscience. By setting the industry standard for in situ single-cell analysis, Vizgen serves as a vital partner for academic institutions and pharmaceutical companies alike, accelerating the pace of drug discovery and translational medicine through high-accuracy, high-efficiency imaging solutions.
How much funding has Vizgen raised?
Vizgen has raised a total of $139.7M across 4 funding rounds:
Series A
$14M
Series B
$37M
Series C
$85.2M
Debt
$3.5M
Series A (2020): $14M with participation from Northpond Ventures and ARCH Venture Partners
Series B (2021): $37M led by ARCH VENTURE PARTNERS, Tao Capital Management, David Walt, and Pura Vida Investments
Series C (2022): $85.2M supported by Sofina, Novalis LifeSciences, Blue Water Life Science Advisors, Northpond Ventures, Tao Capital Management, and ARCH Venture Partners
Debt (2025): $3.5M, investors not publicly disclosed
Key Investors in Vizgen
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs.
Sofina
A private equity and venture capital firm specializing in growth capital and digital transformation across healthcare, consumer goods, and financial services sectors.
Novalis LifeSciences
A boutique investment and advisory firm focused on the life science industry, providing capital and strategic guidance for companies in diagnostics and biopharma therapeutics.
What's next for Vizgen?
With the successful completion of this major strategic investment, Vizgen is well-positioned to expand the reach of its MERSCOPE platform into new clinical and research frontiers. The company is expected to prioritize the scaling of its commercial operations and the further refinement of its imaging throughput to meet the growing demand for high-resolution spatial data. As the life sciences industry increasingly shifts toward single-cell analysis, Vizgen's focus will likely remain on enhancing its software ecosystem and expanding its application library to support complex cell and gene therapy development. This capital injection provides the necessary runway to sustain long-term R&D initiatives, ensuring that Vizgen remains at the vanguard of the spatial biology revolution while navigating the complexities of enterprise-level growth.
See full Vizgen company page
